论文部分内容阅读
目的评价齐多夫定(AZT)高效抗反转氯酶治疗(ART),艾滋病毒携带者/艾滋患者(HIV/AIDS)服用后的不良反应。方法分析总结152例患者经齐多夫定口服后出现不良反应并导致换药的时间、症状体征、占比及处置措施。结果除皮肤色素沉着者外,其他不良反应最早出现时间在2周内,最晚为16周,其中骨髓抑制31例(20.40%),恶心呕吐4例(2.63%),头痛4例(2.63%),面部色素沉着3例(1.97%),持续纳差2例(1.32%)。结论AZT作为HIV/AIDS抗病毒治疗基本药物,其治疗作用和效果确切,但其不良反应在服药人群体中的较高发生率,需引起医学工作者重视,减轻或防止不良反应对患者健康的危害,增强长期服药的依从性。
OBJECTIVE: To evaluate the adverse effects of aztreonam (AZT) and anti-retroviral treatment (ART) and HIV / AIDS patients. Methods A total of 152 cases of patients after oral administration of Zidovudine appeared adverse reactions and lead to change the time, symptoms and signs, accounting for and treatment. Results In addition to skin pigmentation, other adverse reactions first appeared in 2 weeks, the latest 16 weeks, including 31 cases of bone marrow suppression (20.40%), nausea and vomiting in 4 cases (2.63%), headache in 4 cases (2.63% ), Facial pigmentation in 3 cases (1.97%), continuous anorexia in 2 cases (1.32%). Conclusion As an essential anti-virus agent for HIV / AIDS, AZT has definite therapeutic and therapeutic effects. However, the high incidence of AZT in the medication population should be emphasized by medical workers to reduce or prevent the adverse reactions to the patients’ health Hazard, enhance the compliance of long-term medication.